Aptamers Market was valued at USD 2142.8 Million in 2018 and is projected to reach around USD 7456.8 Million by 2028, at a CAGR of 19.50% during the forecast period.
Advancements in aptamer development technologies, increasing R&D investment and the rising number of companies investing in this market are some of the key driving factors responsible for the growth of this market.
Aptamers market report published by the Brandessence Market Research and Consulting Pvt. Ltd. provides the detail information about Aptamers market from various aspects. This report consists of drivers, challenges and opportunities which help the market to grow over the analysis period and recent trends which supports the growth of market. This report consists of regional segmentation with product type and applications.
The chemically synthesized single-standard oligonucleotide (a polynucleotide which contains a relatively small number of nucleotides) are aptamers. Aptamers are developed from more reliable procedures than the manufacture of monoclonal antibodies. These are oligonucleotide which binds to the molecules especially such as protein to be used in numerous applications in field such as research and therapeutics. Numerous advantages offered by these small molecules, in comparison to established antibodies, have also led to higher demand for these molecules across a diverse range of medical applications. They are chemically synthesized, which eliminates batch-to-batch variation and demands less time for development. Due to their extreme versatility they bind to the target that are highly selective and specific including proteins, peptides and carbohydrates. Aptamers are currently being used for the diagnosis of various diseases and detection of the small molecules. Aptamers may be used as pharmaceutical lead section reagents, and functional proteomic levels.
Improvement in aptamer development technologies, increasing research and development expenditure and increasing number of companies investing in this market are some of the key driving factors responsible for the growth of this market. Abundant advantages offered by these small molecules, in comparison to established antibodies, have also led to higher demand for these molecules across a wide range of medical applications. However, many aptamers have failed to meet the requisite safety and efficacy standards in clinical studies. Thus, companies have to terminate their clinical investigation during late-stage clinical studies. This factor may hamper the market growth. Moreover, increasing technological advancements in this field can provide new opportunity for the growth of this market.
Key Players of Aptamers Market are like
Aptamers are peptide and oligonucleotide molecules, helps to bind specific target molecule. Aptamers was coined by Andy Ellington. Aptamers are single-stranded DNA or RNA molecules. Due to its selective and specific nature, Aptamers bind to target molecules. Aptamers are used as macromolecular drugs in research and clinical purposes.
Along with these leading players, there are number of other small and mid-sized players who are coming with huge investment and innovative product launch in the Artificial Organs industry.
Aptagen, LLC is the global leader in aptamer development with more than 25 years of experience in generating high affinity and binding aptamers for small molecules, tissues, proteins and cells. Aptagen was founded in 2004 its operations began after two years in 2006. The company is located in Jacobus, PA., United States. The company creates state-of-the-art target recognition elements for various applications such as diagnostics, therapeutics and bio industrial uses. Aptamers are an emergent technology will become the next evolution in the fields of diagnostics and drug discovery. The company is continually playing a leading role in developing aptamer technology that will help in the treatment of viral infections and diagnosis of various diseases. Aptagen is a leader in the aptamers and built a strong reputation for the positive aptamer results. Aptagen develops aptamers ligands of RNA, DNA, and peptide oligonucleotides. Also, Aptagen offers the industry’s very first Apta-Index at a low-cost service for synthesizing known aptamers for research and development purposes.
Raptamer Discovery is a group of scientists and engineers having years of experience in developing nucleic acids and aptamers. The company offers unique products and services to its customers and committed to deep research to improve aptamer performance. The company’s scientists have published in respected journals like Nature and Nucleic Acid Research. Raptamer Discovery has worked with leading companies and research institutes in the world. Raptamer Discovery group is part of a private company with annual revenues over the past 5 years is more than USD 300 million. The company has several patents in the aptamer industry, providing products with high quality to be hold leading position in the aptamer and antibody markets across research, diganostic, and therapeutic areas. The company is focused on xaptamer development, a modified aptamer that is better, faster, and cost effective than the normal SELEX-based. X-Aptamer is the next generation evolution of aptamer technology.
Aptamer Sciences Inc. was established in 2011 by world class experts. The company is operated in the field of aptamer technology has a strong reputation as a World’s No.1 Biotech Company. Aptamer Sciences is a specialized R&D driven bio Venture Company dedicated to the aptamer technology for the development of innovative therapeutic and diagnostic platforms. The company’s aptamer platforms involve high-quality aptamer technology, aptamer optimization, and development of state-of-the-art aptamer therapeutics and diagnostics. Aptamer Sciences is a leader in aptamer therapeutics and IVD development.
Aptamer Group Ltd. is the world’s leading provider of bespoke nucleic acid aptamer selection and development services. The company has years of experience committed to cutting edge approach and liquid handling platforms to offer aptamer based solutions for changing customers requirements from the fields of pharmaceutical, biotechnology and diagnostic as well as academic and research institutions across the globe. It is a UK based company holding of 3 specialist subsidiaries providing solutions with a focus on a different application area in the life sciences. Aptamer Group is focusing on to be the world-leading supplier of transformational aptamer based solutions to tackle complex challenges faced by customers across the life sciences. The company is using automated platforms, which enables them to perform parallel processing and selection of aptamers against multiple targets.
2bind is one of the leading expert contract research organizations (CRO) for biophysical analytics with 9 years of experience with MST and nanoDSF. The company has highly skilled and passionate scientists from different life-science fields to serve clients’ research and development projects. 2bind Company is a one stop shop for everyone and for those who are interested in protein and RNA-based drug discovery, antibody development, protein analytics, aptamer development or characterization of molecular interactions. 2bind is one of the world’s leading service companies for biophysics-based assays. The company has worked with 6 of the top 10 pharmaceutical companies in the world. Furthermore, 2bind has nearly 250 customers from different industry verticals including Pharma, Biotech and Academia and completed 700 contract research projects.
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us firstname.lastname@example.orgJOIN US
BrandEssence® Market Research and Consulting Pvt ltd.
124, City Road, London EC1V 2NX
© Copyright 2024-25 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®